Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy

Moiseenko, A; Sinadinos, A; Sergijenko, A; Pineault, K; Saleh, A; Nekola, K; Strang, N; Eleftheraki, A; Boyd, AC; Davies, JC; Gill, DR; Hyde, SC; McLachlan, G; Rath, T; Rothe, M; Schambach, A; Hobbie, S; Schuler, M; Maier, U; Thomas, MJ; Mennerich, D; Schmidt, M; Griesenbach, U; Alton, EWFW; Kreuz, S

Journal article

Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy

Abstract:: Rationale and objective: Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. CFTR modulators offer significant improvements, but ∼10% of patients remain nonresponsive or are intolerant. This study provides an analysis of rSIV.F/HN, a lentiviral vector optimised for lung delivery, including CFTR protein expression, functional correction of CFTR defects and genomic integration site analysis in preparation for a first-in-human clinical trial.

Methods: Air–liquid interface cultures of primary human bronchial epithelial cells (HBECs) from CF patients (F508del/F508del), as well as a CFTR-deficient immortalised human lung epithelial cell line mimicking class I (CFTR-null) homozygous mutations, were used to assess transduction efficiency. Quantification methods included a novel proximity ligation assay for CFTR protein expression. For assessment of CFTR channel activity, Ussing chamber studies were conducted. The safety profile was assessed using integration site analysis and in vitro insertional mutagenesis studies.

Results: rSIV.F/HN expressed CFTR and restored CFTR-mediated chloride currents to physiological levels in primary F508del/F508del HBECs as well as in a class I cells. In contrast, the latter could not be achieved by small-molecule CFTR modulators, underscoring the potential of gene therapy for this mutation class. Combination of rSIV.F/HN-CFTR with the potentiator ivacaftor showed a greater than additive effect. The genomic integration pattern showed no site predominance (frequency of occurrence ≤10%), and a low risk of insertional mutagenesis was observed in an in vitro immortalisation assay.

Conclusions: The results underscore rSIV.F/HN as a promising gene therapy vector for CF, providing a mutation-agnostic treatment option.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Moiseenko, A., Sinadinos, A., Sergijenko, A., Pineault, K., Saleh, A., Nekola, K., Strang, N., Eleftheraki, A., Boyd, A. C., Davies, J. C., Gill, D. R., Hyde, S. C., McLachlan, G., Rath, T., Rothe, M., Schambach, A., Hobbie, S., Schuler, M., Maier, U., … Kreuz, S. (2025). Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy. European Respiratory Journal, 65(1).

MLA Style

Moiseenko, A, et al. “Pharmacological and Pre-Clinical Safety Profile of RSIV.F/HN, a Hybrid Lentiviral Vector for Cystic Fibrosis Gene Therapy.” European Respiratory Journal, vol. 65, no. 1, 2025.

Chicago Style

Moiseenko, A, A Sinadinos, A Sergijenko, et al. 2025. “Pharmacological and Pre-Clinical Safety Profile of RSIV.F/HN, a Hybrid Lentiviral Vector for Cystic Fibrosis Gene Therapy.” European Respiratory Journal 65 (1).
Print